Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Merz Therapeutics

Merz Therapeutics Announces First Patients Enrolled in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention
From Merz Therapeutics
Via Business Wire
Health Canada Approves XEOMIN® (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot
From Merz Therapeutics
Via Business Wire
Merz Therapeutics and World Stroke Organization Launch ‘Access to Health’ Initiative to Improve Stroke Care in Africa
From Merz Therapeutics
Via Business Wire
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
From Merz Therapeutics
Via Business Wire
Merz Enters Asset Purchase Agreement With a US-Based Biotech Company
From Merz Therapeutics
Via Business Wire
Merz and Israeli Start-Up Vensica Launch Partnership for Needleless Treatment of Overactive Bladder
From Merz Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.